Q1 Earnings Forecast for TPST Issued By HC Wainwright

Tempest Therapeutics, Inc. (NASDAQ:TPST) – Analysts at HC Wainwright issued their Q1 2026 EPS estimates for Tempest Therapeutics in a research note issued to investors on Tuesday, March 31st. HC Wainwright analyst J. Pantginis anticipates that the company will earn ($0.28) per share for the quarter. The consensus estimate for Tempest Therapeutics’ current full-year earnings is ($1.39) per share. HC Wainwright also issued estimates for Tempest Therapeutics’ Q2 2026 earnings at ($0.30) EPS, Q3 2026 earnings at ($0.35) EPS and Q4 2026 earnings at ($0.39) EPS.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Tempest Therapeutics in a research report on Monday, December 29th. Two equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Reduce” and an average price target of $12.50.

Tempest Therapeutics Trading Down 1.2%

Shares of Tempest Therapeutics stock opened at $1.62 on Thursday. The business’s 50 day simple moving average is $2.31 and its 200-day simple moving average is $5.12. The stock has a market capitalization of $7.98 million, a price-to-earnings ratio of -0.24 and a beta of -2.42. Tempest Therapeutics has a twelve month low of $1.50 and a twelve month high of $12.23.

Tempest Therapeutics (NASDAQ:TPST) last announced its quarterly earnings data on Monday, March 30th. The company reported ($0.62) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.62).

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP bought a new stake in Tempest Therapeutics in the fourth quarter valued at about $33,000. Sabby Management LLC bought a new position in Tempest Therapeutics during the fourth quarter worth about $513,000. Finally, Vanguard Group Inc. boosted its holdings in Tempest Therapeutics by 20.8% during the third quarter. Vanguard Group Inc. now owns 162,560 shares of the company’s stock worth $1,671,000 after buying an additional 27,952 shares during the last quarter. Institutional investors and hedge funds own 22.52% of the company’s stock.

Insider Buying and Selling

In other Tempest Therapeutics news, CEO Matthew Angel acquired 231,482 shares of the company’s stock in a transaction dated Tuesday, March 24th. The stock was bought at an average price of $2.16 per share, for a total transaction of $500,001.12. Following the purchase, the chief executive officer owned 231,482 shares in the company, valued at $500,001.12. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 6.28% of the stock is currently owned by company insiders.

Tempest Therapeutics Company Profile

Tempest Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune‐mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator‐activated receptor alpha (PPARα) and salt‐inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first‐in‐class PPARα antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells.